头颈部鳞状细胞癌患者的血浆谷胱甘肽S-转移酶P1-1水平

Plasma glutathione S-transferase P1-1 levels in patients with head and neck squamous cell carcinoma.

作者信息

Oude Ophuis M B, Mulder T P, Peters W H, Manni J J

机构信息

Department of Otorhinolaryngology/Head and Neck Surgery, Academic Hospital, University of Maastricht, The Netherlands.

出版信息

Cancer. 1998 Jun 15;82(12):2434-8.

PMID:9635537

Abstract

BACKGROUND

Many tumors contain high amounts of the detoxification enzyme glutathione S-transferase P1-1 (GSTP1-1). Elevated levels of GSTP1-1 have also been detected in serum and plasma from patients with gastrointestinal, lung, or head and neck tumors. The authors of this report evaluated the role of GSTP1-1 as a plasma tumor marker in patients with head and neck squamous cell carcinoma (HNSCC) of the larynx, hypopharynx, or oropharnyx and in patients with benign head and neck lesions (BHNL).

METHODS

GSTP1-1 levels were measured in EDTA plasma combined with ethylenediaminetetraacetic acid using a recently developed sensitive and specific sandwich enzyme-linked immunoadsorbent assay. A normal reference level with an upper limit of 21.8 microg GSTP1-1 per liter of plasma was calculated from results obtained with samples from 230 blood donors.

RESULTS

Median GSTP1-1 levels in samples from 53 patients with oral/oropharyngeal SCC (10.6 microg/L; range, 3.7-46.1 microg/L), 12 patients with hypopharyngeal SCC (11.9 microg/L; range, 5.2-146.6 microg/L), and 28 patients with laryngeal SCC (14.4 microg/L; range, 6.4-141.5 microg/L) were significantly elevated when compared with plasma GSTP1-1 levels in samples from 45 patients with BHNL (8.1 microg/L; range, 3.3-32.3 microg/L; P < 0.0001, P < 0.01, and P < 0.0001, respectively). However, only 6 of 53 patients (11%) with oral/oropharyngeal SCC, 1 of 12 patients (8%) with hypopharyngeal SCC, and 6 of 28 patients (21%) with laryngeal SCC had plasma GSTP1-1 levels above the upper limit of the normal reference level. Thus, only 13 of 93 patients (14%) with HNSCC had elevated plasma GSTP1-1 levels overall. No significant relation between plasma GSTP1-1 levels and TNM classification of the tumors was observed.

CONCLUSIONS

GSTP1-1 is not a suitable plasma tumor marker for HNSCC.

摘要

背景

许多肿瘤含有大量解毒酶谷胱甘肽S-转移酶P1-1（GSTP1-1）。在胃肠道、肺部或头颈部肿瘤患者的血清和血浆中也检测到GSTP1-1水平升高。本报告的作者评估了GSTP1-1作为喉、下咽或口咽头颈部鳞状细胞癌（HNSCC）患者以及头颈部良性病变（BHNL）患者血浆肿瘤标志物的作用。

方法

使用最近开发的灵敏且特异的夹心酶联免疫吸附测定法，在结合乙二胺四乙酸的EDTA血浆中测量GSTP1-1水平。根据230名献血者样本的结果计算出正常参考水平，血浆中GSTP1-1的上限为每升21.8微克。

结果

53例口腔/口咽鳞状细胞癌患者样本中的GSTP1-1中位数水平为（10.6微克/升；范围为3.7 - 46.1微克/升），12例下咽鳞状细胞癌患者样本中的GSTP1-1中位数水平为（11.9微克/升；范围为5.2 - 146.6微克/升），28例喉鳞状细胞癌患者样本中的GSTP1-1中位数水平为（14.4微克/升；范围为6.4 - 141.5微克/升），与45例BHNL患者样本中的血浆GSTP1-1水平（8.1微克/升；范围为3.3 - 32.3微克/升）相比，均显著升高（分别为P < 0.0001、P < 0.01和P < 0.0001）。然而，53例口腔/口咽鳞状细胞癌患者中只有6例（11%）、12例下咽鳞状细胞癌患者中只有1例（8%）、28例喉鳞状细胞癌患者中只有6例（21%）的血浆GSTP1-1水平高于正常参考水平上限。因此，93例HNSCC患者中总体只有13例（14%）的血浆GSTP1-1水平升高。未观察到血浆GSTP1-1水平与肿瘤TNM分类之间存在显著关系。